{"id":52874,"date":"2026-01-05T20:40:41","date_gmt":"2026-01-05T12:40:41","guid":{"rendered":"https:\/\/flcube.com\/?p=52874"},"modified":"2026-01-05T20:40:42","modified_gmt":"2026-01-05T12:40:42","slug":"mercks-winrevair-wins-china-nmpa-approval-for-pulmonary-arterial-hypertension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52874","title":{"rendered":"Merck&#8217;s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension"},"content":{"rendered":"\n<p><strong>Merck Sharp &amp;\u202fDohme Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) announced that <strong>Winrevair (sotatercept for injection)<\/strong>, the world\u2019s first and only <strong>Activin Signaling Inhibitor (ASI)<\/strong>, has been <strong>approved by China\u2019s National Medical Products Administration (NMPA)<\/strong>. The drug is indicated for <strong>adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1)<\/strong> with <strong>WHO Functional Class (FC) II-III<\/strong> to improve exercise capacity and functional class.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Winrevair (sotatercept for injection)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Merck Sharp &amp;\u202fDohme (MSD, NYSE: MRK)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Activin Signaling Inhibitor (ASI)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>NMPA approval (Priority Review granted)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>PAH (WHO Group 1), FC II-III adults<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>Phase\u202fIII STELLAR trial<\/td><\/tr><tr><td><strong>Global Precedent<\/strong><\/td><td>Approved by FDA (Mar\u202f2024) and EMA (Aug\u202f2024)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novel-mechanism-of-action\">Novel Mechanism of Action<\/h2>\n\n\n\n<p><strong>ASI Targeting PAH Pathogenesis<\/strong>: Winrevair captures excess <strong>Activin A<\/strong>, restoring imbalanced signaling pathways:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Inhibits aberrant cell proliferation<\/strong> in pulmonary vasculature<\/li>\n\n\n\n<li><strong>Improves vascular structure<\/strong> and restores vessel patency<\/li>\n\n\n\n<li><strong>Reduces pulmonary vascular resistance<\/strong> and right ventricular strain<\/li>\n<\/ul>\n\n\n\n<p>This represents a <strong>paradigm shift<\/strong> from vasodilator\u2011centric therapies (PDE5 inhibitors, ERAs, prostacyclins) to <strong>disease\u2011modifying<\/strong> vascular remodeling.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-china-market-access-pathway\">China Market Access Pathway<\/h2>\n\n\n\n<p><strong>Pre\u2011Approval Access<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>March\u202f2025<\/strong>: Launched in <strong>Lecheng Pilot Zone<\/strong> (Hainan)<\/li>\n\n\n\n<li><strong>December\u202f2025<\/strong>: <strong>Fuwai Hospital<\/strong> (Chinese Academy of Medical Sciences) granted temporary import approval<\/li>\n\n\n\n<li><strong>January\u202f2026<\/strong>: Full NMPA approval enables nationwide commercialization<\/li>\n<\/ul>\n\n\n\n<p><strong>Reimbursement Landscape<\/strong>: Included in <strong>National Reimbursement Drug List (NRDL)<\/strong> since March\u202f2023, ensuring broad patient access.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-in-china\">Market Opportunity in China<\/h2>\n\n\n\n<p><strong>PAH Epidemiology<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: <strong>50,000\u2011100,000<\/strong> diagnosed patients (estimated)<\/li>\n\n\n\n<li><strong>Incidence<\/strong>: <strong>2\u20113 per million<\/strong> annually<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: <strong>&lt;30%<\/strong> of eligible patients receive targeted therapy<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China PAH drug market valued at <strong>\u00a51.2\u202fbillion<\/strong> (US$170M) in 2025, growing at <strong>18% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Winrevair Revenue Projection<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2026<\/strong>: \u00a5400\u2011500\u202fmillion (partial year, NRDL\u2011driven volume)<\/li>\n\n\n\n<li><strong>2027<\/strong>: \u00a5900\u202fmillion\u20111.2\u202fbillion (full year penetration)<\/li>\n\n\n\n<li><strong>2028 Peak<\/strong>: \u00a51.6\u20112.0\u202fbillion (US$225\u2011280M) with <strong>30\u201135%<\/strong> market share<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Mechanism<\/th><th>China Status<\/th><th>Annual Cost (\u00a5)<\/th><\/tr><\/thead><tbody><tr><td><strong>Winrevair<\/strong><\/td><td><strong>Merck<\/strong><\/td><td>ASI (novel)<\/td><td><strong>Approved<\/strong><\/td><td>\u00a5180,000\u2011200,000 (pre\u2011discount)<\/td><\/tr><tr><td><strong>Opsumit<\/strong><\/td><td>Johnson &amp;\u202fJohnson<\/td><td>ERA<\/td><td>Marketed<\/td><td>\u00a5120,000<\/td><\/tr><tr><td><strong>Adempas<\/strong><\/td><td>Bayer<\/td><td>sGC stimulator<\/td><td>Marketed<\/td><td>\u00a5150,000<\/td><\/tr><tr><td><strong>Uptravi<\/strong><\/td><td>Johnson &amp;\u202fJohnson<\/td><td>Prostacyclin<\/td><td>Marketed<\/td><td>\u00a5200,000<\/td><\/tr><tr><td><strong>Generic PDE5i<\/strong><\/td><td>Various<\/td><td>PDE5 inhibitor<\/td><td>Marketed<\/td><td>\u00a520,000\u201140,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: Winrevair\u2019s <strong>novel mechanism<\/strong> offers <strong>potential disease modification<\/strong> vs. symptomatic relief, commanding premium pricing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-amp-manufacturing-strategy\">Commercial &amp; Manufacturing Strategy<\/h2>\n\n\n\n<p><strong>Distribution<\/strong>: Via <strong>MSD Pharma (China) Co., Ltd.<\/strong> utilizing <strong>specialty pharmacy network<\/strong> covering <strong>800+ tertiary hospitals<\/strong>.<\/p>\n\n\n\n<p><strong>Pricing<\/strong>: Expected <strong>50% discount<\/strong> to US pricing (US$190,000\/year) to meet NRDL requirements, translating to <strong>\u00a595,000\u2011110,000<\/strong> annually.<\/p>\n\n\n\n<p><strong>Manufacturing<\/strong>: Global supply chain with <strong>dedicated China inventory<\/strong>; <strong>cold chain logistics<\/strong> for injectable biologic.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Winrevair\u2019s market penetration, revenue forecasts, and competitive positioning in China. Actual results may differ materially due to patient access dynamics, competitive responses, and NRDL pricing negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world\u2019s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52877,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2675,176,903,15,24],"class_list":["post-52874","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck&#039;s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world\u2019s first and only Activin Signaling Inhibitor (ASI), has been approved by China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1) with WHO Functional Class (FC) II-III to improve exercise capacity and functional class.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52874\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck&#039;s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension\" \/>\n<meta property=\"og:description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world\u2019s first and only Activin Signaling Inhibitor (ASI), has been approved by China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1) with WHO Functional Class (FC) II-III to improve exercise capacity and functional class.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52874\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T12:40:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T12:40:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck&#8217;s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension\",\"datePublished\":\"2026-01-05T12:40:41+00:00\",\"dateModified\":\"2026-01-05T12:40:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874\"},\"wordCount\":431,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0501.webp\",\"keywords\":[\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52874#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52874\",\"name\":\"Merck's Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0501.webp\",\"datePublished\":\"2026-01-05T12:40:41+00:00\",\"dateModified\":\"2026-01-05T12:40:42+00:00\",\"description\":\"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world\u2019s first and only Activin Signaling Inhibitor (ASI), has been approved by China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1) with WHO Functional Class (FC) II-III to improve exercise capacity and functional class.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52874\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck's Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52874#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck&#8217;s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck's Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension - Insight, China&#039;s Pharmaceutical Industry","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world\u2019s first and only Activin Signaling Inhibitor (ASI), has been approved by China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1) with WHO Functional Class (FC) II-III to improve exercise capacity and functional class.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52874","og_locale":"en_US","og_type":"article","og_title":"Merck's Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension","og_description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world\u2019s first and only Activin Signaling Inhibitor (ASI), has been approved by China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1) with WHO Functional Class (FC) II-III to improve exercise capacity and functional class.","og_url":"https:\/\/flcube.com\/?p=52874","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-05T12:40:41+00:00","article_modified_time":"2026-01-05T12:40:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52874#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52874"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck&#8217;s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension","datePublished":"2026-01-05T12:40:41+00:00","dateModified":"2026-01-05T12:40:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52874"},"wordCount":431,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52874#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0501.webp","keywords":["Merck Sharp &amp; Dohme","MSD","NYSE: MRK","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52874#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52874","url":"https:\/\/flcube.com\/?p=52874","name":"Merck's Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52874#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52874#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0501.webp","datePublished":"2026-01-05T12:40:41+00:00","dateModified":"2026-01-05T12:40:42+00:00","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) announced that Winrevair (sotatercept for injection), the world\u2019s first and only Activin Signaling Inhibitor (ASI), has been approved by China\u2019s National Medical Products Administration (NMPA). The drug is indicated for adult patients with Pulmonary Arterial Hypertension (PAH, WHO Group 1) with WHO Functional Class (FC) II-III to improve exercise capacity and functional class.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52874#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52874"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52874#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0501.webp","width":1080,"height":608,"caption":"Merck's Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52874#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck&#8217;s Winrevair Wins China NMPA Approval for Pulmonary Arterial Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52874"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52874\/revisions"}],"predecessor-version":[{"id":52878,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52874\/revisions\/52878"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52877"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}